Key result
Dynamically regulated long non-coding RNAs offer potential as novel circulating biomarkers and therapeutic targets in CVD.
Why the study?
Studies have increasingly described the critical regulation and key role of long non-coding RNAs in the development and progression of multiple cardiac disorders, warranting a summary of their mechanisms, biomarker utility, and therapeutic potential.
This review highlights the emerging role of long non-coding RNAs in cardiac dysfunction, their potential as biomarkers, and as novel therapeutic targets in heart diseases.
Caution against premature clinical use of lncRNA biomarkers; extends evidence base for therapeutic targeting in cardiovascular disease.
During the past decade numerous studies highlighted the importance of long non-coding RNAs (lncRNAs) in orchestrating cardiovascular cell signaling. Classified only by a transcript size of more than 200 nucleotides and their inability to code for proteins, lncRNAs constitute a heterogeneous group of RNA molecules with versatile functions and interaction partners, thus interfering with numerous endogenous signaling pathways. Intrinsic transcriptional regulation of lncRNAs is not only specific for different cell types or developmental stages, but may also change in response to stress factors or under pathological conditions. Regarding the heart, an increasing number of studies described the critical regulation of lncRNAs in multiple cardiac disorders, underlining their key role in the development and progression of cardiac diseases. In this review article, we will summarize functional cardiac lncRNAs with a detailed view on their molecular mode of action in pathological cardiac remodeling and myocardial infarction. In addition, we will discuss the use of circulating lncRNAs as biomarkers for prognostic and diagnostic purposes and highlight the potential of lncRNAs as a novel class of therapeutic targets for therapeutic purpose in heart diseases.
No takes yet. Share an insight, caveat, or question.
Hobuß et al. (2019) conducted a review in Cardiovascular disease. Long non-coding RNAs (lncRNAs) was evaluated. Long non-coding RNAs are dynamically regulated upon initiation and progression of cardiovascular diseases, offering potential as novel circulating biomarkers and therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: